Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I

Journal of Bacteriology

Volumn 184, Issue 8, 2002, Pages 2167-2172

  Boshoff, Helena I ^a   Mizrahi, Valerie ^a   Barry III, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLOROPYRAZINAMIDE; AMIDE; BENZOIC ACID; CELL EXTRACT; FATTY ACID; FATTY ACID SYNTHASE; ISOENZYME; NICOTINIC ACID; PYRAZINAMIDE; PYRAZINE DERIVATIVE; PYRAZINOIC ACID; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; BIOACCUMULATION; CATALYSIS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME PURIFICATION; FATTY ACID SYNTHESIS; HYDROLYSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STRESS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; HYDROGEN-ION CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE;

ACTINOBACTERIA (CLASS); MYCOBACTERIUM; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 0036207006     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.184.8.2167-2172.2002     Document Type: Article

References (43)

1. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis
2. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides
3. Purification, gene cloning, targeted knockout, overexpression, and biochemical characterization of the major pyrazinamidase from Mycobacterium smegmatis
4. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
5. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic
6. Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages
7. In vitro antimycobacterial activity of 5-chloropyrazinamide
8. Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Mycobacterium microti OV254
9. Efficacy of intermittent pyrazinamide in experimental murine tuberculosis
10. Bacteriologic basis of short-course chemotherapy for tuberculosis
11. New experimental regimens for preventive therapy of tuberculosis
12. Mycobacterium smegmatis has two pyrazinamidase enzymes, PncA and PzaA
13. +-ATPases
14. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocytederived macrophages
15. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations
16. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
17. Metabolism of nicotinamide adenine dinucleotide in human and bovine strains of Mycobacterium tuberculosis
18. Thermodynamic parameters and shape of the mycobacterial polymethylpolysaccharide-fatty acid complex
19. Purification and characterization of an unusually large fatty acid synthase from Mycobacterium tuberculosis var. bovis BCG
20. The intracellular activation of pyrazinamide and nicotinamide
21. Structure of a mycobacterial polysaccharide-fatty acyl-CoA complex: Nuclear magnetic resonance studies
22. The effect of pyrazinamide (Aldinamide) on experimental tuberculosis in mice
23. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. 11. The conversion of tuberculosis infection to the latent state by the administration of pyrazinamide and a companion drug
24. Activation of pyrazinamide and nicotinamide in acidic environments in vitro
25. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid
26. The action of antituberculosis drugs in short-course chemotherapy
27. Intracellular fate of Mycobacterium avium: Use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization on phagosomal pH and phagosomelysosome interaction
28. Cerulenin
29. Intracellular pH regulation by Mycobactorium smegmatis and Mycobacterium bovis BCG
30. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system
31. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method
32. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis
33. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus
34. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis
35. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms
36. Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar
37. The pncA gene from naturally pyrazinamide-resistant Mycobacterium avium encodes pyrazinamidase and confers pyrazinamide susceptibility to resistant M. tuberculosis complex organisms
38. Reduced pyrazinamidase activity and the natural resistance of Mycobacterium kansasii to the antituberculosis drug pyrazinamide
39. Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid
40. Inactivation of the inhA-encoded fatty acid synthase Il (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis
41. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide
42. Genetics of drug resistance in Mycobacterium tuberculosis
43. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis